Thank you, Brad. We’re on Slide 8, the key M&A criteria slide. I’ll begin my remarks by expanding on Brad’s comment about our M&A strategy. Over the course of our history, Ward and the team have demonstrated a long track record of value creation by acquiring, integrating and optimizing asset-light businesses with high free cash flow models. As we have mentioned previously, we take a very targeted approach focused on 3 buckets. First, geographic expansion and expanding core products in new markets; second, introducing new products in existing core markets; and third, expanding our portfolio of safety products outside of our current law enforcement and military markets, into attractive adjacencies within the safety and survivability landscape. In evaluating potential acquisitions, we favor businesses with a leading market position that have a leading and defensible technology and strong brand recognition. In addition, it is critical that a target business has a recurring revenue profile, high cash generation relative to EBITDA is asset light and has an attractive return on invested capital. Following the acquisition of Cyalume, which I will discuss in a moment, we are currently in the process of actively evaluating other compelling opportunities. In terms of M&A valuations, we expect that in this environment, we could see multiples compress. Moving to Slide 9. In line with this criteria that I just outlined, we recently completed the acquisition of Cyalume the leading supplier of chemical illumination solutions to U.S. and NATO military forces among other commercial markets. The purchase price of the acquisition was $35 million, subject to customary adjustments for net working capital, transaction expenses and indebtedness and was funded through withdrawal on our existing credit facilities. The business is expected to generate approximately $25 million in pro forma revenues for the calendar year ending December 31, 2022. Cyalume has a rich history with roots tracing back to the origins of chemical illumination over 60 years ago. Today, the company provides light sticks, chemical, luminescent ammunition and infrared devices to the U.S. and NATO military forces among other commercial and law enforcement markets. Warren has followed Cyalume for over 2 decades, and it’s a business that’s perfectly aligned with our lifesaving mission. As a leading supplier of chemical light products to the U.S. Department of Defense, NATO and Allied nations, Cyalume is entrenched in combat in recurring military training applications. The addition of Cyalume advances our strategic focus on increasing wallet share with our current military, law enforcement and commercial customer base and adds a resilient recurring revenue stream to our portfolio. Moving forward, we’re focused on the integration process. Our top priorities include working with the functional teams on the first 100-day basics of integration, utilizing the 80/20 rule to prioritize factors that will produce the best results optimizing growth by leveraging Cyalume and Cadre selling teams and implementing core Cadre operating tools. We look forward to expanding Cyalume product penetration across new military and commercial markets leveraging Cyalume deep competency and strong customer relationships, along with our selling teams, expertise and global resources. On Slides 10 and 11, we detail our first quarter 2022 results. Q1 net sales of $104.5 million exceeded the high end of our guidance range we provided last quarter. The decline versus last year first quarter was primarily the result of a large U.S. federal duty gear shipment in Q1 2021, combined with strong commercial demand and higher demand for crowd control products last year. Gross profit margin was 38.5% for the first quarter, mainly driven by the less favorable portfolio mix that Brad discussed earlier, partially offset by price. I’d like to highlight that we expect margin expansion in the second half of 2022 to be similar to the strong margins we saw in the first half of 2021. Net loss was $10.2 million for the quarter ended March 31, 2022, and which reflects a $23.6 million stock compensation expense, and illustrating our success generating significant free cash flow, our first quarter EBITDA conversion of 92% remained strong and was in line with our guidance. I’d like to remind everyone that we generally don’t have seasonality in our business, and more importantly, from a cash generation perspective, we have very low CapEx needs at approximately 1% of revenue annually. Turning to the next slide, we illustrate anticipated top line and adjusted EBITDA growth for the full year 2022. As Warren and Brad mentioned, we have upwardly revised our 2022 net sales and adjusted EBITDA ranges. Based on their midpoints, we expect 5% annual growth for both full year net sales and adjusted EBITDA. On Slide 12, we present our capital structure as of March 31. Our net debt was $147 million, and we believe our net leverage around 2x provides a significant financial flexibility to grow organically and more importantly, inorganically through acquisitions. We provide our updated guidance on Slide 13. As we mentioned, based on our strong and increasing backlog, expectation that our product portfolio mix normalizes moving forward. and our progress executing strategic objectives related to M&A, we’ve increased our 2022 outlook. Cadre expects to generate net sales in 2022 between $441 million and $452 million and adjusted EBITDA in 2022 of between $72.5 million and $77.5 million. Additionally, we expect adjusted EBITDA conversion to be between 92% and 95% for the full year 2022. I’ll now turn it back to Brad for concluding comments.